New York City, New York Sep 28, 2022 (Issuewire.com) - In the last few years, the pharmaceutical industry has witnessed a dramatical increase in the development of drug molecules, but the process can be a time-consuming and expensive task. Artificial intelligence (AI) technologies provide new opportunities for identifying and generating high-quality antibody drugs in less time, and Creative Biolabs has developed an original AI-augmented drug discovery platform that guides antibody design and accelerates the discovery of better antibody therapeutics.
With a team of experts focused on antibody-drug discovery, this AI-augmented drug discovery platform provides superior services for selecting and validating drug targets, designing new drugs, predicting the drug synthetic routes, assessing drug pharmacological properties, as well as evaluating drug safety and efficacy in clinical use.
Creative Biolabs has integrated advanced artificial intelligence, big data, and phage display techniques, aiming to help clients accelerate the discovery of rare antibodies. The expert team develops the machine learning (ML) algorithms covering the growing number of biophysical data for various antibody targets, thus predicting antibodies that bind to a given antigen target with high affinity, and ensuring the antibody sequences with a higher level of the therapeutic potential and lower level of safety and manufacturing risks.
- AI-based Antibody Screening
The expert team at Creative Biolabs has collected the published data and different kinds of AI models to train the self-established algorithm. This platform is quick and accurate in identifying the interaction between potential antibodies and disease states, predicting antibody-antigen binding, creating optimized antibody sequences, and accelerating antibody drug discovery. The managers are specialized in designing high-quality custom AI-based antibody screening assays with different formats, endpoints, and parameters for any specific requirement.
The antibody engineering service portfolio mainly includes antibody affinity maturation, scFv/Fab construction, antibody stability improvement, and other antibody specialization and modification services. With the latest published antibody usage data to constantly update the AI model and modify the parameter for the cutting-edge AI algorithm, Creative Biolabs can optimize antibody sequence, and expand and recover the diversity of existing antibodies with improved antibody quality and manufacturability.
Besides, small-molecule design and optimization services and model training data services are within the one-stop AI-aided solutions for antibody and small molecule drug discovery. More information about AI solutions for drug development can be found at https://ai.creative-biolabs.com/.
About Creative Biolabs
Recognized as a reliable partner in antibody drug discovery and manufacturing serving academia and industry clients all over the world, Creative Biolabs has established an experimentally-certified AI platform, providing intelligent solutions to accelerate drug discovery and development covering antibody drugs and small molecule drugs. AI solutions will help the pharma and biotechnology companies to greatly cut costs, streamline the workflow, and save valuable research time.
Media Contact
Creative Biolabs marketing@creative-biolabs.com https://ai.creative-biolabs.com/
